JP2006516622A5 - - Google Patents

Download PDF

Info

Publication number
JP2006516622A5
JP2006516622A5 JP2006502975A JP2006502975A JP2006516622A5 JP 2006516622 A5 JP2006516622 A5 JP 2006516622A5 JP 2006502975 A JP2006502975 A JP 2006502975A JP 2006502975 A JP2006502975 A JP 2006502975A JP 2006516622 A5 JP2006516622 A5 JP 2006516622A5
Authority
JP
Japan
Prior art keywords
group
groups
alkyl
optionally substituted
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006502975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006516622A (ja
JP4560035B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/001927 external-priority patent/WO2004069158A2/en
Publication of JP2006516622A publication Critical patent/JP2006516622A/ja
Publication of JP2006516622A5 publication Critical patent/JP2006516622A5/ja
Application granted granted Critical
Publication of JP4560035B2 publication Critical patent/JP4560035B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006502975A 2003-01-27 2004-01-23 置換ピラゾール、このような化合物を含有する組成物及び使用方法 Expired - Fee Related JP4560035B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44282803P 2003-01-27 2003-01-27
PCT/US2004/001927 WO2004069158A2 (en) 2003-01-27 2004-01-23 Substituted pyrazoles, compositions containing such compounds and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010027448A Division JP5260569B2 (ja) 2003-01-27 2010-02-10 置換ピラゾール、このような化合物を含有する組成物及び使用方法

Publications (3)

Publication Number Publication Date
JP2006516622A JP2006516622A (ja) 2006-07-06
JP2006516622A5 true JP2006516622A5 (enExample) 2007-11-01
JP4560035B2 JP4560035B2 (ja) 2010-10-13

Family

ID=32850762

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006502975A Expired - Fee Related JP4560035B2 (ja) 2003-01-27 2004-01-23 置換ピラゾール、このような化合物を含有する組成物及び使用方法
JP2010027448A Expired - Fee Related JP5260569B2 (ja) 2003-01-27 2010-02-10 置換ピラゾール、このような化合物を含有する組成物及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010027448A Expired - Fee Related JP5260569B2 (ja) 2003-01-27 2010-02-10 置換ピラゾール、このような化合物を含有する組成物及び使用方法

Country Status (8)

Country Link
US (2) US7572922B2 (enExample)
EP (1) EP1590336B1 (enExample)
JP (2) JP4560035B2 (enExample)
AT (1) ATE490244T1 (enExample)
AU (2) AU2004210127B2 (enExample)
CA (1) CA2513102C (enExample)
DE (1) DE602004030318D1 (enExample)
WO (1) WO2004069158A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2513102C (en) 2003-01-27 2011-03-22 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
EP1615895A4 (en) 2003-04-03 2007-11-07 Merck & Co Inc BIARYLSUBSTITUTED PYRAZOLE AS SODIUM CHANNEL BLOCKER
NZ551405A (en) * 2004-06-04 2009-06-26 Merck & Co Inc Pyrazole derivatives, compositions containing such compounds and methods of use
CN1980665A (zh) * 2004-07-07 2007-06-13 默克公司 吡唑酰胺衍生物，包含这些化合物的组合物和使用方法
CN1993124A (zh) * 2004-07-22 2007-07-04 默克公司 取代吡唑、含有这种化合物的组合物及其应用
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
WO2006122319A2 (en) 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2613522A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
JP2009502923A (ja) 2005-07-26 2009-01-29 メルク エンド カムパニー インコーポレーテッド 置換ピラゾールを合成するための方法
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
CA2645639A1 (en) 2006-03-23 2007-10-04 Merck & Co. Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2418202B1 (en) 2006-03-31 2014-01-29 Novartis AG (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors
CA2650619A1 (en) 2006-05-16 2007-11-29 Merck And Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP5399262B2 (ja) * 2006-12-08 2014-01-29 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒおよびｆｘｒのモジュレーター
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
CN105566265A (zh) 2007-02-09 2016-05-11 症变治疗公司 新颖的胰高血糖素受体拮抗剂
AU2008282032B2 (en) * 2007-08-02 2014-08-07 Recordati Ireland Limited Novel heterocyclic compounds as mGlu5 antagonists
US8232413B2 (en) * 2007-09-12 2012-07-31 Merck Sharp & Dohme Corp. Process for the production of a crystalline glucagon receptor antagonist compound
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
JP5450083B2 (ja) * 2007-11-01 2014-03-26 武田薬品工業株式会社 複素環化合物
AU2008340227B2 (en) 2007-12-26 2013-05-09 Elster Electricity, Llc. Optimized data collection in a wireless fixed network metering system
KR101616140B1 (ko) 2008-03-05 2016-04-27 다케다 야쿠힌 고교 가부시키가이샤 복소환 화합물
JP2011520897A (ja) 2008-05-16 2011-07-21 シェーリング コーポレイション グルカゴン受容体アンタゴニスト、組成物およびそれらの使用方法
CA2728095A1 (en) 2008-07-17 2010-01-21 Asahi Kasei Pharma Corporation Pyrazole-containing tricyclic compounds as antagonists of an ep1 receptor
ES2615481T3 (es) 2008-08-13 2017-06-07 Metabasis Therapeutics, Inc. Antagonistas de glucagón
WO2010030722A1 (en) * 2008-09-15 2010-03-18 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010039789A1 (en) * 2008-10-03 2010-04-08 Schering Corporation Spiro-imidazolone derivatives as glucagon receptor antagonists
JP2012505163A (ja) * 2008-10-10 2012-03-01 ロンザ リミテッド ２−アルキル−３−アロイル−５−ニトロ−ベンゾフランの調製方法
WO2010093535A1 (en) 2009-02-12 2010-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010098994A1 (en) 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010144664A1 (en) * 2009-06-12 2010-12-16 Schering Corporation Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
EP2480077B1 (en) 2009-09-22 2015-02-18 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
WO2011143057A1 (en) 2010-05-11 2011-11-17 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
UY33476A (es) * 2010-06-30 2012-02-29 Ironwood Pharmaceuticals Inc Estimuladores de sgc
WO2012064559A1 (en) 2010-11-09 2012-05-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
MX2013006768A (es) 2010-12-23 2013-07-22 Pfizer Moduladores de receptor de glucagon.
CA2825102C (en) 2011-02-08 2016-03-08 Pfizer Inc. Glucagon receptor modulators
KR20140023441A (ko) 2011-07-22 2014-02-26 화이자 인코포레이티드 퀴놀린일 글루카곤 수용체 조절제
WO2013101830A1 (en) 2011-12-27 2013-07-04 Ironwood Pharmaceuticals, Inc. 2 - benzyl, 3 - (pyrimidin- 2 -yl) substituted pyrazoles useful as sgc stimulators
EP3065736B1 (en) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
EP3154956A4 (en) 2014-06-12 2018-01-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
TWI757332B (zh) * 2016-09-06 2022-03-11 比利時商健生藥品公司 使用作為升糖素受體拮抗劑之吲唑衍生物
TW201811752A (zh) * 2016-09-06 2018-04-01 比利時商健生藥品公司 用作升糖素受體拮抗劑之吲唑衍生物
CN111954560A (zh) 2018-02-13 2020-11-17 配体药物公司 胰高血糖素受体拮抗剂
CA3243048A1 (en) * 2021-12-23 2025-04-08 Vib Vzw 2-PYRAZOLE, ANILINES AND RELATED ANALOGUES TO INHIBIT YAP/TAZ-TEAD
WO2025034531A1 (en) * 2023-08-04 2025-02-13 The University Of Vermont And State Agricultural College Small molecule allosteric modulator to pac1 receptor and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303993D0 (en) * 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
BE1009189A3 (fr) * 1995-03-14 1996-12-03 Solvay Procede pour la fabrication d'un corps creux.
JPH11514651A (ja) 1995-10-31 1999-12-14 メルク エンド カンパニー インコーポレーテッド 置換ピリジルピロール、前記化合物を含む組成物及び使用方法
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
EP0959886A4 (en) 1996-11-20 2001-05-02 Merck & Co Inc TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS
CA2271941A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles and methods of use
CA2271963A1 (en) 1996-11-20 1998-05-28 Linda L. Chang Triaryl substituted imidazoles, compositions containing such compounds and methods of use
DE69719544T2 (de) * 1996-12-12 2003-11-06 Banyu Pharmaceutical Co., Ltd. Pyrazolderivate
YU53899A (sh) 1997-04-18 2002-10-18 G.D. Searle & Co. Primena inhibitora ciklooksigenaze-2 u prevenciji kardiovaskularnih poremećaja
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
CN1282319A (zh) * 1997-10-09 2001-01-31 小野药品工业株式会社 氨基丁酸衍生物
WO1999032448A1 (en) 1997-12-19 1999-07-01 Amgen Inc. Substituted pyridine and pyridazine compounds and their pharmaceutical use
EP1121129B1 (en) 1998-09-17 2008-09-03 Bristol-Myers Squibb Company METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND ASSOCIATED COMBINATIONS
CN1356977A (zh) 1999-05-17 2002-07-03 诺沃挪第克公司 胰高血糖素拮抗剂/反向激动剂
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
JP2003506443A (ja) * 1999-08-10 2003-02-18 バイエルクロップサイエンス株式会社 除草性テトラゾリノン誘導体
HUP0203165A3 (en) * 1999-11-10 2004-03-29 Takeda Pharmaceutical 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
IL153181A0 (en) 2000-06-23 2003-06-24 Novo Nordisk As Glucagon antagonists/inverse agonists
US6562807B2 (en) * 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU7705601A (en) 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
AU2002223501A1 (en) 2000-11-17 2002-05-27 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
ITMI20010733A1 (it) * 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
EP1463715A1 (en) 2001-12-03 2004-10-06 Novo Nordisk A/S Novel glucagon antagonists
US6881746B2 (en) * 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
AU2002351730A1 (en) 2001-12-19 2003-06-30 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
WO2003053938A1 (en) 2001-12-20 2003-07-03 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
AU2003239609B2 (en) 2002-02-01 2008-10-23 Dainippon Sumitomo Pharma Co., Ltd. 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
AU2003233780A1 (en) 2002-06-27 2004-01-19 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
JP4890761B2 (ja) 2002-07-19 2012-03-07 バクスター・インターナショナル・インコーポレイテッド 腹膜透析を実施するためのシステムおよび方法
EP1400243A1 (en) 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
WO2004050039A2 (en) 2002-12-04 2004-06-17 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
CA2513102C (en) 2003-01-27 2011-03-22 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
CN1794989A (zh) 2003-04-14 2006-06-28 药物研发有限责任公司 用于治疗糖尿病的n－(((((1,3－噻唑－2－基)氨基)羰基)苯基)磺酰基)苯丙氨酸衍生物及相关化合物
DE10317108A1 (de) 2003-04-14 2004-11-11 Mutzbauer, Till S., Dr. Dr.med. Transdermal applizierbares Beruhigungs- und Sedierungsmittel
EP1626717A4 (en) 2003-05-09 2009-09-09 Merck & Co Inc BENZIMIDAZOLE, COMPOSITIONS AND METHOD OF ADMINISTRATION CONTAINING SUCH COMPOUNDS
NZ551405A (en) 2004-06-04 2009-06-26 Merck & Co Inc Pyrazole derivatives, compositions containing such compounds and methods of use
CN1993124A (zh) * 2004-07-22 2007-07-04 默克公司 取代吡唑、含有这种化合物的组合物及其应用
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Similar Documents

Publication Publication Date Title
JP2006516622A5 (enExample)
CA2513102A1 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
TWI354666B (en) Heterocyclic aspartyl protease inhibitors
JP2006509015A5 (enExample)
JP2013513613A5 (enExample)
CA2557538A1 (en) Benzimidazole derivative and use as an angiotensin ii receptor antagonist
KR940701383A (ko) 질소 함유 헤테로사이클릭 화합물의 플루오로알콕시벤질아미노 유도체
JP2013528602A5 (enExample)
RU2011105422A (ru) Дейтерированные бензилбензольные производные и способы применения
JP2008526724A5 (enExample)
AR065276A1 (es) Herbicidas de n-oxidos de piridina sustituidos
RU2009126745A (ru) Производные сульфонилфенил-2н-{1,2,4}оксадиазол-5-она, способы их получения и их применение в качестве фармацевтических средств
JP2002535323A5 (enExample)
JP2009535358A5 (enExample)
JP2009521483A5 (enExample)
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
JPWO2020061101A5 (enExample)
JP2011511840A5 (enExample)
JP2009533410A5 (enExample)
UA103894C2 (ru) Соединения и способ для снижения уровня мочевой кислоты
TW202334116A (zh) 一種取代的苯丙酸衍生物及其用途
DE602004030004D1 (de) Verbindungen zur behandlung von stoffwechselstörungen
JP2011503006A5 (enExample)
RU2002107318A (ru) Новые фенилпиперазины
RU2314292C2 (ru) Производные азетидина в качестве антагонистов ccr-3 рецептора